Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

Author's Avatar
Nov 08, 2022

Study will evaluate PORT-2 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with front-line as well as refractory non-small cell lung cancer (NSCLC)